Published in Proc Natl Acad Sci U S A on June 07, 2007
Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation (2008) 1.84
Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol (2009) 1.79
Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res (2010) 1.32
Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res (2013) 1.27
Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells. J Biol Chem (2008) 1.25
The role of Neuregulin-1beta/ErbB signaling in the heart. Exp Cell Res (2008) 1.23
Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation (2012) 1.14
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget (2012) 1.14
Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. BMC Cancer (2008) 1.06
X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. Mol Cancer Ther (2010) 1.05
Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury. PLoS One (2012) 1.04
Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem. Drug Discov Today (2008) 0.97
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. Mol Cancer Ther (2011) 0.96
GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochem Pharmacol (2012) 0.93
ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat (2011) 0.91
Cardiac side effects of anticancer treatments: new mechanistic insights. Curr Heart Fail Rep (2012) 0.86
Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics. Int J Mol Sci (2012) 0.81
Targeting HER2 in breast cancer: overview of long-term experience. Int J Womens Health (2010) 0.80
Potent cardioprotective effect of the 4-anilinoquinazoline derivative PD153035: involvement of mitochondrial K(ATP) channel activation. PLoS One (2010) 0.80
Cardiomyocyte autophagy and cancer chemotherapy. J Mol Cell Cardiol (2013) 0.79
Targeted therapies in breast cancer: are heart and vessels also being targeted? Breast Cancer Res (2012) 0.79
Susceptibility to ATP depletion of primary proximal tubular cell cultures derived from mice lacking either the α1 or the α2 isoform of the catalytic domain of AMPK. BMC Nephrol (2013) 0.76
Lapatinib for the treatment of breast cancer in the People's Republic of China. Onco Targets Ther (2014) 0.76
AMP-Activated Protein Kinase Signalling in Cancer and Cardiac Hypertrophy. Cardiovasc Pharm Open Access (2015) 0.76
AMP-activated protein kinase and energy balance in breast cancer. Am J Transl Res (2017) 0.75
Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open (2016) 0.75
Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond. Can J Cardiol (2016) 0.75
Targeted treatment of advanced and metastaticbreast cancer with lapatinib. Onco Targets Ther (2008) 0.75
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
TSC2 mediates cellular energy response to control cell growth and survival. Cell (2003) 20.21
Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell (1999) 19.48
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J (2004) 10.82
Akt stimulates aerobic glycolysis in cancer cells. Cancer Res (2004) 9.35
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med (2006) 9.07
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res (2006) 7.18
Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest (2000) 7.06
The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol (2000) 6.29
Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature (1995) 5.91
Multiple essential functions of neuregulin in development. Nature (1995) 5.66
The AMP-activated protein kinase pathway--new players upstream and downstream. J Cell Sci (2004) 5.65
A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell (2001) 5.57
Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature (1995) 5.51
Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett (2003) 5.22
AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem (2002) 3.81
Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J (1994) 3.42
ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med (2002) 3.36
Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation (1998) 3.14
Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol (2004) 3.12
Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest (2005) 2.98
PPARgamma coactivator 1beta/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity. Proc Natl Acad Sci U S A (2003) 2.89
The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor alpha (ERRalpha). J Biol Chem (2003) 2.81
Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res (2004) 2.79
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol (2005) 2.77
Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol (2002) 2.73
AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol Cell Biol (2005) 2.56
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A (2002) 2.32
The PGC-1-related protein PERC is a selective coactivator of estrogen receptor alpha. J Biol Chem (2002) 2.28
Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol (1994) 2.20
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene (2004) 1.89
A role for estrogen-related receptor alpha in the control of mitochondrial fatty acid beta-oxidation during brown adipocyte differentiation. J Biol Chem (1997) 1.65
Characterization of 5'AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta (1996) 1.50
Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol (2004) 1.46
Regulation of ion channels by protein tyrosine phosphorylation. Am J Physiol Heart Circ Physiol (2001) 1.39
Herceptin and the heart--a molecular modifier of cardiac failure. N Engl J Med (2006) 1.33
A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Proc Natl Acad Sci U S A (2006) 1.33
Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis: a potential strategy to prevent the development of cardiac hypertrophy. Can J Physiol Pharmacol (2005) 1.08
Targeted cancer therapeutics: the heartbreak of success. Nat Med (2006) 1.06
Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr Top Med Chem (2006) 0.99
Regulation of c-Rel nuclear localization by binding of Ca2+/calmodulin. Mol Cell Biol (2003) 0.98
Mitochondrial biogenesis in mtDNA-depleted cells involves a Ca2+-dependent pathway and a reduced mitochondrial protein import. FEBS J (2005) 0.89
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 17.98
EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol (2006) 10.39
Cyclin E and survival in patients with breast cancer. N Engl J Med (2002) 6.44
The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors (2006) 5.58
A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 4.35
Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer (2008) 4.25
The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta (2006) 4.06
p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol (2011) 3.73
Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol (2010) 3.61
Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol (2011) 3.52
Longitudinal analysis of neural network development in preterm infants. Cereb Cortex (2010) 3.47
Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene (2004) 3.27
The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res (2003) 3.18
Vimentin-dependent spatial translocation of an activated MAP kinase in injured nerve. Neuron (2005) 3.09
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A (2006) 2.86
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol (2007) 2.85
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol (2005) 2.77
Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem (2003) 2.77
The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol (2007) 2.74
The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol (2010) 2.72
Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene (2002) 2.50
DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. Mol Cell (2007) 2.48
A large set of Finnish affected sibling pair families with type 2 diabetes suggests susceptibility loci on chromosomes 6, 11, and 14. Diabetes (2004) 2.46
The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol (2005) 2.45
A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J (2002) 2.42
Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys (2004) 2.41
Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature (2008) 2.32
p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. EMBO J (2006) 2.23
LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J (2004) 2.20
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J (2002) 2.17
An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline. Neuropathology (2011) 2.16
EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci Signal (2010) 2.16
Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A (2005) 2.14
Hsp90 recognizes a common surface on client kinases. J Biol Chem (2006) 2.12
CXCL12 secretion by bone marrow stromal cells is dependent on cell contact and mediated by connexin-43 and connexin-45 gap junctions. Nat Immunol (2011) 2.05
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A (2005) 2.00
Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta (2007) 1.97
Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol Cell (2011) 1.89
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res (2007) 1.88
The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta (2010) 1.85
The ERK Cascade: Distinct Functions within Various Subcellular Organelles. Genes Cancer (2011) 1.74
Identification and characterization of a general nuclear translocation signal in signaling proteins. Mol Cell (2008) 1.73
Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes Dev (2004) 1.73
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A (2009) 1.71
Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA (2008) 1.69
Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc Natl Acad Sci U S A (2010) 1.60
Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol Cell Biol (2006) 1.59
Vimentin binding to phosphorylated Erk sterically hinders enzymatic dephosphorylation of the kinase. J Mol Biol (2006) 1.57
The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle (2004) 1.54
Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Curr Biol (2003) 1.50
Roles for growth factors in cancer progression. Physiology (Bethesda) (2010) 1.48
Childhood ADHD predicts risky sexual behavior in young adulthood. J Clin Child Adolesc Psychol (2006) 1.47
p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res (2004) 1.47
Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep (2004) 1.46
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A (2010) 1.46
AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene (2002) 1.44
The mitogen-activated protein kinase signaling cascade: from bench to bedside. Isr Med Assoc J (2002) 1.44
Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. Proc Natl Acad Sci U S A (2003) 1.44
Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. J Biol Chem (2006) 1.42
Endocytosis and cancer. Cold Spring Harb Perspect Biol (2013) 1.40
Interactions of beta and gamma ENaC with Nedd4 can be facilitated by an ERK-mediated phosphorylation. J Biol Chem (2002) 1.37
MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle (2007) 1.37
The subcellular localization of MEK and ERK--a novel nuclear translocation signal (NTS) paves a way to the nucleus. Mol Cell Endocrinol (2009) 1.37
Atypical PKC-zeta regulates SDF-1-mediated migration and development of human CD34+ progenitor cells. J Clin Invest (2005) 1.36
The controlled generation of functional basal forebrain cholinergic neurons from human embryonic stem cells. Stem Cells (2011) 1.32
Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res (2008) 1.30
Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem (2004) 1.30
Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett (2010) 1.30
Cost/success projections for US biodefense countermeasure development. Nat Biotechnol (2008) 1.30
An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Curr Biol (2009) 1.30
Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer (2004) 1.30
ERK1c regulates Golgi fragmentation during mitosis. J Cell Biol (2006) 1.28
Protein-protein interactions in the regulation of the extracellular signal-regulated kinase. Mol Biotechnol (2005) 1.28
Systems biology of growth factor-induced receptor endocytosis. Traffic (2008) 1.26
Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol (2007) 1.25
Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res (2006) 1.23
Activation of MAPK cascades by GnRH: ERK and Jun N-terminal kinase are involved in basal and GnRH-stimulated activity of the glycoprotein hormone LHbeta-subunit promoter. Endocrinology (2002) 1.20
ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture. Endocrinology (2002) 1.19
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Res (2013) 1.18
Down-regulation of p53 by double-stranded RNA modulates the antiviral response. J Virol (2005) 1.17
Nuclear extracellular signal-regulated kinase 1 and 2 translocation is mediated by casein kinase 2 and accelerated by autophosphorylation. Mol Cell Biol (2011) 1.17
EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J (2011) 1.17
Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies. Biochem J (2007) 1.16
miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med (2012) 1.14
Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem (2004) 1.14
BMP-mediated inhibition of FGF signaling promotes cardiomyocyte differentiation of anterior heart field progenitors. Development (2010) 1.14
Coupled pre-mRNA and mRNA dynamics unveil operational strategies underlying transcriptional responses to stimuli. Mol Syst Biol (2011) 1.13
A positive role of the PI3-K/Akt signaling pathway in PC12 cell differentiation. Mol Cells (2004) 1.11
Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol (2004) 1.11
The ERK signaling cascade--views from different subcellular compartments. Biofactors (2009) 1.11
Variation in reproductive traits of members of the genus Canis with special attention to the domestic dog (Canis familiaris). Behav Processes (2012) 1.10